Accelrys Announces New Re-Seller Agreement In Computer Aided Engineering
SAN DIEGO--(BUSINESS WIRE)--Accelrys, Inc. (NASDAQ: ACCL - News), a leading provider of scientific business intelligence software and services, today announced that it has entered into a re-seller agreement with CADFEM, an engineering solutions provider for computer aided engineering based in Germany, to deliver modeling and simulation software solutions to CADFEM customers in Europe.
Under the terms of the agreement, CADFEM will add Accelrys' Materials Studio ™ software to the set of multi-scale tools it offers to its materials engineering customers in Germany, Austria and Switzerland. The collaboration aims to deliver increases in efficiency and productivity, while delivering cost savings by focusing on variations in the materials as they relate to requirements of engineering design. This approach will result in more lightweight, and at the same time reliable and robust materials solutions for applications ranging from transportation to biomechanics.
"The addition of a new re-seller is a key step in our growth strategy to continually enhance our distribution channel through a network of OEM and re-seller partnerships," said Accelrys' President and Chief Executive Officer Mark J. Emkjer. "CADFEM, the number one reseller of Ansys, is well known for introducing innovative technologies to its well-established base of engineering customers. Not only does this agreement help us move further into the engineering industry, but it establishes a foothold for us with CADFEM's existing user base."
About Accelrys, Inc.
Headquartered in San Diego, California, Accelrys develops scientific business intelligence software and solutions for the life sciences, energy, chemicals, aerospace, and consumer products industries. Its customers include many Fortune 500 companies and other commercial entities, as well as academic and government entities. The company has a vast portfolio of computer-aided design modeling and simulation offerings which assist our customers in conducting scientific experiments ‘in silico' in order to reduce the duration and cost of discovering and developing new drugs and materials. Accelrys' scientific business intelligence platform underlies most of its computer-aided design modeling and simulation offerings. Its platform can be used with its own products, its competitors' products and its customers' proprietary predictive science products. Its flexibility, ease-of-use and advanced chemical, text and image analysis and reporting capabilities enable our customers to mine, aggregate, analyze and report scientific data from disparate sources, thereby better utilizing scientific data within their organizations. For more information about Accelrys, visit its website at http://accelrys.com/
For more information about CADFEM, visit its website at http://cadfem.de
This press release contains forward-looking statements. Such statements, including statements relating to the agreement with CADFEM, potential customers and markets, are subject to risks and uncertainties including, but not limited to, the risks that the agreement will not result in additional revenue, and other risks and uncertainties described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K and any subsequent interim filings. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys disclaims any intent or obligation to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Copyright 2008 Business Wire All Rights Reserved.